Advertisement

Fatal combination of mitragynine and quetiapine – a case report with discussion of a potential herb-drug interaction

  • Rhome L. Hughes
Case Report
  • 47 Downloads

Abstract

Kratom is a plant with dose-dependent mixed stimulant and opioid properties whose pharmacologic characteristics and social impact continue to be described. The main active isolate of kratom is mitragynine, an indole-containing alkaloid with opioid-like effects. Kratom toxicity and kratom-associated fatalities have been described, including those in association with additional drugs. In this paper we describe the case of a 27-year-old man who was found deceased with a toxic blood concentration of quetiapine in conjunction with the qualitative presence of mitragynine. Investigative and autopsy findings suggested perimortem hyperthermia and seizure-like activity. Kratom toxicity and kratom-associated fatalities are being increasingly reported. Experiments with kratom extracts have shown inhibitory effects upon hepatic CYP enzymes, leading to previous speculation of the potential for clinically significant interactions between kratom and a wide array of medications. Herein is described a fatal case of quetiapine toxicity complicated by mitragynine use. The potential ability of mitragynine to alter the pharmacokinetics of a prescription medication via inhibition of its hepatic metabolism is discussed.

Keywords

Kratom Mitragynine Quetiapine Overdose CYP 

Notes

Compliance with ethical standards

Conflict of interest

None.

Ethical approval

Not applicable.

Informed consent

Not applicable.

References

  1. 1.
    Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, et al. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther. 2015;9:2421–9.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Prozialeck W, Jivan J, Andurkar S. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112:792–9.PubMedGoogle Scholar
  3. 3.
    Pantano F, Tittarelli R, Mannocchi G, Zaami S, Ricci S, Giorgetti R, et al. Hepatotoxicity induced by “the 3Ks”: kava, kratom and khat. Int J Mol Sci. 2016;17:580.CrossRefGoogle Scholar
  4. 4.
    Kratom (Mitragyna speciosa korth). 2013. http://www.deadiversion.usdoj.gov/drug_chem_info/kratom.pdf. Accessed 7 July 2016.
  5. 5.
    Castillo A, Payne JD, Nugent K. Posterior reversible leukoencephalopathy syndrome after kratom ingestion. Proc (Baylor Univ Med Cent). 2017;30:355–7.CrossRefGoogle Scholar
  6. 6.
    Galbis-Reig D. A case report of kratom addiction and withdrawal. WMJ. 2016;115:49–52.PubMedGoogle Scholar
  7. 7.
    Food and Drug Administration. 2018. Statement for FDA Commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse [Press release]. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm595622.htm. Accessed 2 Aug 2018.
  8. 8.
    Aggarwal G, Robertson E, McKinlay J, Walter E. Death from kratom toxicity and the possible role of intralipid. J Intensive Care Soc. 2018;19:61–3.CrossRefGoogle Scholar
  9. 9.
    Domingo O, Roider G, Stover A, Graw M, Musshoff F, Sachs H, et al. Mitragynine concentrations in two fatalities. Forensic Sci Int. 2017;271:e1–7.CrossRefGoogle Scholar
  10. 10.
    Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016;130:127–38.CrossRefGoogle Scholar
  11. 11.
    Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following kratom (mitragynine speciosa korth) exposure. J Med Toxicol. 2010;6:424–6.CrossRefGoogle Scholar
  12. 12.
    Baselt RC. Disposition of toxic drugs and chemicals in man. 8th ed. Foster City (CA): Biomedical Publications; 2008.Google Scholar
  13. 13.
    Molina DK. Handbook of forensic toxicology for medical examiners. Boca Raton: CRC Press; 2010.Google Scholar
  14. 14.
    Gortney JS, Fagan A, Kissack JC. Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother. 2009;43:785–91.CrossRefGoogle Scholar
  15. 15.
    Raffa RB. Kratom and other mitragynines: the chemistry and pharmacology of opioids from a non-opium source. Boca Raton: CRC Press; 2015.Google Scholar
  16. 16.
    Harmon TJ, Benitez JG, Krenzelok EP, Cortes-Belen E. Loss of consciousness from acute quetiapine overdosage. J Toxicol Clin Toxicol. 1998;36:599–602.CrossRefGoogle Scholar
  17. 17.
    Devane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509–22.CrossRefGoogle Scholar
  18. 18.
    Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009;37:254–8.CrossRefGoogle Scholar
  19. 19.
    Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61:58–69.CrossRefGoogle Scholar
  20. 20.
    Hanapi NA, Ismail S, Mansor SM. Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities. Pharm Res. 2013;5:241–6.Google Scholar
  21. 21.
    Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391–6.PubMedGoogle Scholar
  22. 22.
    Hasselstrom J, Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metabol Drug Interact. 2006;21:187–211.CrossRefGoogle Scholar
  23. 23.
    Meyer MR, Wagmann L, Schneider-Daum N, Loretz B, de Souza Carvalho C, Lehr CM, et al. P-glycoprotein interactions of novel psychoactive substances – stimulation of ATP consumption and transport across Caco-2 monolayers. Biochem Pharmacol. 2015;94:220–6.CrossRefGoogle Scholar
  24. 24.
    Schmitt U, Kirschbaum KM, Poller B, Kusch-Poddar M, Drewe J, Hiemke C, et al. In vitro p-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Pharmacol Biochem Behav. 2012;102:312–20.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University of North Dakota School of Medicine and Health SciencesGrand ForksUSA

Personalised recommendations